Who owns MYRIAD GENETICS INC (MYG)? Elite investor 13F holders
2 tracked elite investors reported holding MYRIAD GENETICS INC as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | MYRIAD GENETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 26163694.00 USD | 4582083.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | MYRIAD GENETICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Tudor Investment | MYRIAD GENETICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 255123.00 USD | 44680.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.